Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.47 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
P.1.17 (Gamma)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
P.1.17 (Gamma)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.119.2 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.119.2 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.121 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.121 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.14 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.14 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.119 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.119 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.46.2 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.46.2 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.114 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.114 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
DY.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DY.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.5.2.48NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.2.48NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.5.2.49NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.2.49NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BF.7.14.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.14.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.2.3.11NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.2.3.11NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
FL.4.11NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.4.11NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BF.7.14NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.14NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.5.59NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5.59NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.24.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.24.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.17.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.17.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.5.63NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5.63NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
FL.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.5NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
FU.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FU.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.16NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XBB.1.16NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BN.1.3.6NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BN.1.3.6NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BN.1.3.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BN.1.3.8NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
JN.1.57NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.57NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BF.7.14.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used